NAFLD. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Patients will receive a 40 or 80 mg nanomicelle sina curcumin soft gel daily for 8 weeks. Intervention 2: Control group: The placebo will be taken once a day , whic
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 16 Years
Inclusion criteria
Inclusion criteria: Non-alcoholic fatty liver disease confirmed by a pediatric gastroenterologist Patient parents' consent to participate in this project
Exclusion criteria
Exclusion criteria: Allergy to curcumin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of Alanine aminotransferase. Timepoint: 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of liver transaminase.;Serum level of Aspartate aminotransferase. Timepoint: 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of liver transaminase. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body mass index. Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Measurement of height and weight and ratio of weight to square of height.;Fasting Blood Sugar. Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of serum Fasting Blood Sugar.;Lipid profile(Chol,TG,HDL,LDL). Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of serum lipid profile(Chol, TG, HDL,LDL).;Alkaline phosphatase. Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of serum Alkaline phosphatase. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Khademian
Esfahan University of Medical Sciences
Outcome results
None listed